197 related articles for article (PubMed ID: 34977341)
1. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
Veinalde R; Pidelaserra-Martí G; Moulin C; Jeworowski LM; Küther L; Buchholz CJ; Jäger D; Ungerechts G; Engeland CE
Mol Ther Oncolytics; 2022 Mar; 24():43-58. PubMed ID: 34977341
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.
Veinalde R; Grossardt C; Hartmann L; Bourgeois-Daigneault MC; Bell JC; Jäger D; von Kalle C; Ungerechts G; Engeland CE
Oncoimmunology; 2017; 6(4):e1285992. PubMed ID: 28507792
[TBL] [Abstract][Full Text] [Related]
4. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
5. Chimerization of the Anti-Viral CD8
Vile R; Webb M; van Vloten J; Evgin L; Sangsuwannukul T; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Yerovi MC; McNiven M; Monga S; Borad M; Roberts L
Res Sq; 2023 Nov; ():. PubMed ID: 38045348
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
[TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
11. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
[TBL] [Abstract][Full Text] [Related]
13. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
14. IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity.
El-Sayes N; Walsh S; Vito A; Reihani A; Ask K; Wan Y; Mossman K
Mol Ther Oncolytics; 2022 Jun; 25():16-30. PubMed ID: 35399605
[TBL] [Abstract][Full Text] [Related]
15. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
16. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
17. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists.
Backhaus PS; Veinalde R; Hartmann L; Dunder JE; Jeworowski LM; Albert J; Hoyler B; Poth T; Jäger D; Ungerechts G; Engeland CE
Viruses; 2019 Oct; 11(10):. PubMed ID: 31623390
[TBL] [Abstract][Full Text] [Related]
18. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
19. Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.
Mabbitt J; Holyer ID; Roper JA; Nilsson UJ; Zetterberg FR; Vuong L; Mackinnon AC; Pedersen A; Slack RJ
Front Immunol; 2023; 14():1250559. PubMed ID: 37701441
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]